DB:A71

Stock Analysis Report

Executive Summary

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs.

Snowflake

Flawless balance sheet with limited growth.

Share Price & News

How has Ascendis Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: A71 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

2.5%

A71

-1.6%

DE Biotechs

0.8%

DE Market


1 Year Return

90.7%

A71

-8.9%

DE Biotechs

9.0%

DE Market

Return vs Industry: A71 exceeded the German Biotechs industry which returned -8.9% over the past year.

Return vs Market: A71 exceeded the German Market which returned 9% over the past year.


Shareholder returns

A71IndustryMarket
7 Day2.5%-1.6%0.8%
30 Day21.4%-1.5%6.3%
90 Day0%-8.3%14.4%
1 Year90.7%90.7%-8.7%-8.9%12.4%9.0%
3 Year442.7%442.7%49.7%47.8%25.6%14.5%
5 Yearn/a-1.5%-4.6%41.0%21.8%

Price Volatility Vs. Market

How volatile is Ascendis Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ascendis Pharma undervalued compared to its fair value and its price relative to the market?

7.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A71's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate A71's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: A71 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: A71 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A71's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: A71 is overvalued based on its PB Ratio (7.2x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Ascendis Pharma forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

40.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A71 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: A71 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: A71 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: A71's revenue (72.6% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: A71's revenue (72.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A71 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Ascendis Pharma performed over the past 5 years?

-46.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if A71 has high quality earnings.

Growing Profit Margin: A71's current net profit margins (-931.6%) are higher than last year (-17395.3%).


Past Earnings Growth Analysis

Earnings Trend: A71 is unprofitable, and losses have increased over the past 5 years at a rate of -46.2% per year.

Accelerating Growth: Unable to compare A71's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A71 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: A71 has a negative Return on Equity (-26.44%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Ascendis Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: A71's short term assets (€702.8M) exceeds its short term liabilities (€60.6M)

Long Term Liabilities: A71's short term assets (702.8M) exceeds its long term liabilities (31.5M)


Debt to Equity History and Analysis

Debt Level: A71 is debt free.

Reducing Debt: A71 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: A71 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if A71's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A71 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A71 has sufficient cash runway for 2.991859 years if free cash flow continues to reduce at historical rates of -38.8% each year.


Next Steps

Dividend

What is Ascendis Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate A71's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate A71's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A71's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A71's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of A71's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Ascendis Pharma's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Jan Mikkelsen (59yo)

11.9yrs

Tenure

0

Mr. Jan Møller Mikkelsen serves as the Chief Executive Officer, President, Executive Director and Member of Executive Board of Ascendis Pharma A/S since December 2007. Mr. Mikkelsen served as Chief Executi ...


Management Age and Tenure

4.3yrs

Average Tenure

53yo

Average Age

Experienced Management: A71's management team is considered experienced (4.3 years average tenure).


Board Age and Tenure

5.0yrs

Average Tenure

54yo

Average Age

Experienced Board: A71's board of directors are considered experienced (5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Sell€3,387,34114 Aug 19
OrbiMed Advisors LLC
EntityCompany
Shares32,900
Max Price€102.96
Buy€11,486,44012 Mar 19
OrbiMed Advisors LLC
EntityCompany
Shares182,500
Max Price€63.81

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.4%.


Management Team

  • Jan Mikkelsen (59yo)

    President

    • Tenure: 11.9yrs
  • Michael Jensen (48yo)

    Chairman

    • Tenure: 11.8yrs
  • Ami Knoefler

    Head of Global Communications

    • Tenure: 0yrs
  • Flemming Jensen (58yo)

    Senior Vice President of Product Supply

    • Tenure: 4.3yrs
  • Lotte Sønderbjerg (58yo)

    Chief Administrative Officer & Senior VP

    • Tenure: 11.9yrs
  • Peter Rasmussen (50yo)

    VP of Finance & Principal Accounting Officer

    • Tenure: 5.7yrs
  • Scott Smith (45yo)

    CFO, Senior VP & Member of Executive Board

    • Tenure: 3.3yrs
  • Kennett Sprogøe (40yo)

    Senior VP and Head of Innovation & Research

    • Tenure: 3.8yrs
  • Tom Larson (57yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 1.6yrs
  • Juha Punnonen (53yo)

    Senior VP & Head of Oncology

    • Tenure: 1.2yrs

Board Members

  • Jim Healy (54yo)

    Independent Director

    • Tenure: 5yrs
    • Compensation: €56.84k
  • Albert Cha (47yo)

    Independent Director

    • Tenure: 5yrs
    • Compensation: €50.96k
  • Jan Mikkelsen (59yo)

    President

    • Tenure: 11.9yrs
  • Michael Jensen (48yo)

    Chairman

    • Tenure: 11.8yrs
  • Birgitte Volck (57yo)

    Independent Director

    • Tenure: 3.5yrs
    • Compensation: €39.20k
  • Lisa Morrison (51yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: €43.12k
  • Lars Holtug (60yo)

    Independent Director

    • Tenure: 1yrs
    • Compensation: €7.67k

Company Information

Ascendis Pharma A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ascendis Pharma A/S
  • Ticker: A71
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.407b
  • Listing Market Cap: US$4.910b
  • Shares outstanding: 47.74m
  • Website: https://www.ascendispharma.com

Number of Employees


Location

  • Ascendis Pharma A/S
  • Tuborg Boulevard 12
  • Hellerup
  • Capital Region of Denmark
  • 2900
  • Denmark

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ASNDNasdaqGS (Nasdaq Global Select)YesADR REPR 1 ORD SHARES DKK1.00USUSDJan 2015
A71DB (Deutsche Boerse AG)YesADR REPR 1 ORD SHARES DKK1.00DEEURJan 2015
ASND NBMV (Bolsa Mexicana de Valores)YesADR REPR 1 ORD SHARES DKK1.00MXMXNJan 2015

Biography

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which has completed Phase II ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/12 21:36
End of Day Share Price2019/11/12 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.